These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9106176)

  • 1. Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.
    Ragnhammar P
    Med Oncol; 1996 Sep; 13(3):167-76. PubMed ID: 9106176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
    Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
    Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
    Fukuda M; Horibe K; Furukawa K
    Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
    Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).
    Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Ljungberg A; Hjelm AL; Fagerberg J; Lindemalm C; Osterborg A; Wersäll P
    Acta Oncol; 1991; 30(8):923-31. PubMed ID: 1777244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
    Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
    Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
    Kushner BH; Cheung NK
    Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.
    Frödin JE; Fagerberg J; Hjelm Skog AL; Liljefors M; Ragnhammar P; Mellstedt H
    Hybrid Hybridomics; 2002 Apr; 21(2):99-101. PubMed ID: 12031098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
    Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
    Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
    Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
    Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
    Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity.
    Young DA; Lowe LD; Clark SC
    J Immunol; 1990 Jul; 145(2):607-15. PubMed ID: 2142182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.
    Cheung IY; Hsu K; Cheung NK
    J Clin Oncol; 2012 Feb; 30(4):426-32. PubMed ID: 22203761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
    Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
    Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
    Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
    Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia.
    Emanuel PD; Bates LJ; Zhu SW; Castleberry RP; Gualtieri RJ; Zuckerman KS
    Exp Hematol; 1991 Nov; 19(10):1017-24. PubMed ID: 1915702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
    Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
    Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.